Literature DB >> 18461674

Analysis of CD137 and CD137L expression in human primary tumor tissues.

Qun Wang1, Pin Zhang, Qixia Zhang, Xiaoyan Wang, Jianfeng Li, Chunhong Ma, Wensheng Sun, Lining Zhang.   

Abstract

AIM: To assess the expression of CD137 and CD137L in human primary tumor tissues and their potential role in tumor immunity.
METHODS: Expression of CD137 and CD137L was assessed by immunohistochemistry in frozen sections of 12 human normal tissues, 15 benign tumors of epithelial or mesenchymal origin (adenoma and leiomyoma), and 36 malignant tumors of epithelial origin (squamous cell carcinoma and adenocarcinoma). The expression of CD137L on 9 human tumor cell lines (3 hepatocarcinoma, 2 lung carcinoma, 2 colon carcinoma, 1 lymphoma, and 1 leukemia) was detected by reverse transcription polymerase chain reaction. To analyze the role of CD137L expressed on tumor cells, we co-cultured tumor cells expressing CD137L with activated T lymphocytes expressing CD137 or with Chinese hamster ovary cells expressing CD137 and then detected by ELISA the levels of cytokines (IL-8, IFN-gamma) secreted by tumor cells or activated T cells.
RESULTS: The expression of CD137 and CD137L was observed only in human benign (2/15, 3/15) or malignant tumors (15/36, 21/36), but not in normal tissues (0/12, 0/12). CD137 was expressed on the vessel walls within tumor tissues, whereas CD137L was expressed on tumor cells. The expression of CD137 and CD137L was more common in malignant tumors, especially in moderate or low-differentiated tumors. Furthermore, CD137L expression found on tumor cell lines was functional because the ligation of CD137L on lung squamous carcinoma cells L78 with CD137 on T cells induced IFN-gamma production by T cells, and ligation of CD137L on hepatocarcinoma cells HepG2.2.15 with CD137 triggered tumor cells to produce IL-8.
CONCLUSION: CD137 and CD137L are expressed in different human primary tumor tissues, suggesting that they may influence the progression of tumors.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18461674      PMCID: PMC2359873          DOI: 10.3325/cmj.2008.2.192

Source DB:  PubMed          Journal:  Croat Med J        ISSN: 0353-9504            Impact factor:   1.351


  21 in total

1.  Expression and costimulatory effects of the TNF receptor superfamily members CD134 (OX40) and CD137 (4-1BB), and their role in the generation of anti-tumor immune responses.

Authors:  Vadim Y Taraban; Tania F Rowley; Lyn O'Brien; H T Claude Chan; Linsey E Haswell; Michael H A Green; Alison L Tutt; Martin J Glennie; Aymen Al-Shamkhani
Journal:  Eur J Immunol       Date:  2002-12       Impact factor: 5.532

2.  4-1BB ligand induces cell division, sustains survival, and enhances effector function of CD4 and CD8 T cells with similar efficacy.

Authors:  J L Cannons; P Lau; B Ghumman; M A DeBenedette; H Yagita; K Okumura; T H Watts
Journal:  J Immunol       Date:  2001-08-01       Impact factor: 5.422

3.  CD137 expression in tumor vessel walls. High correlation with malignant tumors.

Authors:  K Broll; G Richter; S Pauly; F Hofstaedter; H Schwarz
Journal:  Am J Clin Pathol       Date:  2001-04       Impact factor: 2.493

4.  4-1BB ligand-mediated costimulation of human T cells induces CD4 and CD8 T cell expansion, cytokine production, and the development of cytolytic effector function.

Authors:  Tao Wen; Jacob Bukczynski; Tania H Watts
Journal:  J Immunol       Date:  2002-05-15       Impact factor: 5.422

5.  Constitutive expression of functional 4-1BB (CD137) ligand on carcinoma cells.

Authors:  H R Salih; S G Kosowski; V F Haluska; G C Starling; D T Loo; F Lee; A A Aruffo; P A Trail; P A Kiener
Journal:  J Immunol       Date:  2000-09-01       Impact factor: 5.422

Review 6.  Biochemical and immunological characteristics of 4-1BB (CD137) receptor and ligand and potential applications in cancer therapy.

Authors:  G Sica; L Chen
Journal:  Arch Immunol Ther Exp (Warsz)       Date:  1999       Impact factor: 4.291

7.  Blockade of 4-1BB (CD137)/4-1BB ligand interactions increases allograft survival.

Authors:  H R Cho; B Kwon; H Yagita; S La; E A Lee; J-E Kim; H Akiba; J Kim; J-H Suh; D S Vinay; S-A Ju; B-S Kim; R S Mittler; K Okumura; B S Kwon
Journal:  Transpl Int       Date:  2004-07-31       Impact factor: 3.782

8.  ILA, the human 4-1BB homologue, is inducible in lymphoid and other cell lineages.

Authors:  H Schwarz; J Valbracht; J Tuckwell; J von Kempis; M Lotz
Journal:  Blood       Date:  1995-02-15       Impact factor: 22.113

9.  4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12.

Authors:  Diego Laderach; Amy Wesa; Anne Galy
Journal:  Cell Immunol       Date:  2003-11       Impact factor: 4.868

10.  Anti-4-1BB monoclonal antibody enhances rejection of large tumor burden by promoting survival but not clonal expansion of tumor-specific CD8+ T cells.

Authors:  Kenneth F May; Lieping Chen; Pan Zheng; Yang Liu
Journal:  Cancer Res       Date:  2002-06-15       Impact factor: 12.701

View more
  18 in total

Review 1.  Immunomodulation in leukemia: cellular aspects of anti-leukemic properties.

Authors:  M Maleknia; A Valizadeh; S M S Pezeshki; N Saki
Journal:  Clin Transl Oncol       Date:  2019-05-24       Impact factor: 3.405

2.  CD137 ligand-mediated reverse signaling inhibits proliferation and induces apoptosis in non-small cell lung cancer.

Authors:  Yingying Qian; Dong Pei; Ting Cheng; Changling Wu; Xiaolin Pu; Xiaofeng Chen; Yiqian Liu; Hong Shen; Weiwei Zhang; Yongqian Shu
Journal:  Med Oncol       Date:  2015-01-29       Impact factor: 3.064

3.  Autoinducer-2 of gut microbiota, a potential novel marker for human colorectal cancer, is associated with the activation of TNFSF9 signaling in macrophages.

Authors:  Qing Li; Wei Peng; Jiao Wu; Xianfei Wang; Yixing Ren; Huan Li; Yan Peng; Xiaowei Tang; Xiangsheng Fu
Journal:  Oncoimmunology       Date:  2019-06-10       Impact factor: 8.110

4.  Inherited TNFSF9 deficiency causes broad Epstein-Barr virus infection with EBV+ smooth muscle tumors.

Authors:  Benjamin Fournier; Akihiro Hoshino; Anne-Sophie Defachelles; Bénédicte Neven; Julie Bruneau; Camille Bachelet; Mathieu Fusaro; Roman Klifa; Romain Lévy; Christelle Lenoir; Claire Soudais; Capucine Picard; Stéphane Blanche; Martin Castelle; Despina Moshous; Thierry Molina; Sylvain Latour
Journal:  J Exp Med       Date:  2022-06-03       Impact factor: 17.579

5.  CD137 is expressed in follicular dendritic cell tumors and in classical Hodgkin and T-cell lymphomas: diagnostic and therapeutic implications.

Authors:  Matthew W Anderson; Shuchun Zhao; Aharon G Freud; Debra K Czerwinski; Holbrook Kohrt; Ash A Alizadeh; Roch Houot; Denize Azambuja; Irene Biasoli; José Carlos Morais; Nelson Spector; Hernan F Molina-Kirsch; Roger A Warnke; Ronald Levy; Yasodha Natkunam
Journal:  Am J Pathol       Date:  2012-09       Impact factor: 4.307

Review 6.  Armored CAR T-cells: utilizing cytokines and pro-inflammatory ligands to enhance CAR T-cell anti-tumour efficacy.

Authors:  Oladapo O Yeku; Renier J Brentjens
Journal:  Biochem Soc Trans       Date:  2016-04-15       Impact factor: 5.407

7.  Analysis of CD137L and IL-17 expression in tumor tissue as prognostic indicators for gliblastoma.

Authors:  Xiangli Cui; Zhiqin Xu; Zhigang Zhao; Dali Sui; Xiaohui Ren; Qiming Huang; Jiazhen Qin; Limin Hao; Zhenguang Wang; Li Shen; Song Lin
Journal:  Int J Biol Sci       Date:  2013-01-16       Impact factor: 6.580

Review 8.  4-1BB Agonists: Multi-Potent Potentiators of Tumor Immunity.

Authors:  Todd Bartkowiak; Michael A Curran
Journal:  Front Oncol       Date:  2015-06-08       Impact factor: 6.244

9.  Combination immune therapies to enhance anti-tumor responses by NK cells.

Authors:  Ashley Mentlik James; Adam D Cohen; Kerry S Campbell
Journal:  Front Immunol       Date:  2013-12-23       Impact factor: 7.561

10.  Amelioration of Japanese encephalitis by blockage of 4-1BB signaling is coupled to divergent enhancement of type I/II IFN responses and Ly-6C(hi) monocyte differentiation.

Authors:  Seong Bum Kim; Jin Young Choi; Jin Hyoung Kim; Erdenebelig Uyangaa; Ajit Mahadev Patil; Sang-Youel Park; John Hwa Lee; Koanhoi Kim; Young Woo Han; Seong Kug Eo
Journal:  J Neuroinflammation       Date:  2015-11-24       Impact factor: 8.322

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.